# RNN 1st Gen Model Endo International plc Pharmaceutical preparations

Stock predictor AI models:
63.64% successful of 66 deals
$ 4.16 Last close price
at 18-oct-2021


Model's trade recommendations 2.09% Return for period

-17.54% Annual return

$1.26B Market Cap

β 0.34  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 2.09%
52wk return 11.42%
52wk Range
Sortino ratio -0.44
Sharpe ratio -0.40
Norm. RMSE 1.77%
Downside risk 30.25%
Volatility 0.00%
  • HOLD Analysts consensus recommendation

Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Endo International plc (ENDP) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for ENDP model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ENDP.

Model is being retrained on a daily basis.

Float 223M
P/E 1.47
Shares Outstanding 224M
% Held by Insiders 0.50%
% Held by Institutions 93.95%
EPS (last reported FY) $3.84
EPS (last reported Q) $0.77
EPS, estimated (last reported Q) $0.62
Total revenues $3 B
Net income $-2 B